Treatment for Solid Organ Transplant

Phase-Based Progress Estimates
Cedars Sinai Medical Center, Los Angeles, CA
Solid Organ Transplant+1 More
All Sexes
What conditions do you have?

Study Summary

The purpose the research is to evaluate whether patients who receive a Donation after Circulatory Death (DCD) heart for cardiac transplantation using either normothermic regional perfusion (NRP) or direct procurement and perfusion (DPP) have similar outcomes as patients who receive Donation after Brain Death (DBD) heart using standard cold storage. The study will also evaluate whether DCD procured hearts have a meaningful impact on hearts available for transplantation at our center.

Eligible Conditions

  • Solid Organ Transplant

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1 year

1 year
Assess the practical, financial and logistical viability of using NRP vs. DPP for the procurement of DCD donor hearts.
30 days post-heart transplant
Evaluate the safety of utilizing DCD donor hearts as compared to DBD donor hearts for transplantation.

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

30 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Trial Background

Fardad Esmailian, Surgical Director, Heart Transplantation and Mechanical Circulatory Support
Principal Investigator
Cedars-Sinai Medical Center
Closest Location: Cedars Sinai Medical Center · Los Angeles, CA
Photo of Cedars Sinai Medical Center   1Photo of Cedars Sinai Medical Center   2Photo of cedars sinai medical center  3
2016First Recorded Clinical Trial
2 TrialsResearching Solid Organ Transplant
203 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are male or female, aged 18 years of age or older listed for primary heart transplant.
You are authorized to use and disclose protected health information.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.